Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrated good glycemic efficacy in type 2 diabetes mellitus (T2DM) patients recent years [1]. This evidence concerns the gene GCG and type 2 diabetes mellitus.